AHK-Cu
Aeterna does not sell peptides. External link, vendor independently verified.
Mechanism
AHK-Cu is not a synthetic invention. It is a fragment – three amino acids cleaved from the N-terminal domain of human serum albumin, carrying a copper(II) ion in a stable coordination complex. The body already knows this molecule. What research has attempted to understand is precisely what it instructs.
Copper(II) coordination is the foundational mechanism: histidine chelates Cu²⁺ in a square-planar complex that neutralizes ionic toxicity while preserving cofactor availability for lysyl oxidase. Lysyl oxidase cross-links collagen and elastin — the structural basis of tensile matrix integrity.
TGF-β and VEGF upregulation drives the proliferative and angiogenic response observed in preclinical wound models. TGF-β recruits fibroblasts and myofibroblasts; VEGF drives capillary ingrowth into healing tissue.
MMP-2 and MMP-9 modulation governs the remodeling phase: AHK-Cu shifts matrix metalloproteinase activity in dermal fibroblast cultures, clearing damaged collagen ahead of new deposition. The balance is concentration-dependent and context-sensitive.
Anagen-phase prolongation is the follicular expression of the same pathways active in cutaneous repair. AHK-Cu sustains dermal papilla viability and perifollicular vascularization through VEGF and copper-dependent enzymatic signaling.
What we observe
Reported results for skin and hair
The following observations are drawn from preclinical models, in vitro studies, and a limited body of cosmeceutical research. No outcome listed here constitutes a clinical claim. Patterns are reported; individual responses are not predicted.
01
Collagen Neosynthesis
02
Wound Closure
03
Angiogenic Signaling
04
Follicle Retention
05
Antioxidant Enzymes
06
Barrier Integrity
Evidence
The science behind AHK-Cu
The published record on AHK-Cu spans five decades, from Pickart’s foundational isolation work through contemporary wound-biology and cosmeceutical research. The preclinical literature is substantive; controlled human trials remain sparse. Three studies of particular mechanistic relevance are presented below.
Copper peptide GHK-Cu and AHK-Cu stimulate collagen synthesis and wound healing in dermal fibroblast cultures
Human dermal fibroblasts treated with AHK-Cu at 1–10 nM concentrations showed statistically significant increases in type I procollagen secretion compared to untreated controls. Lysyl oxidase activity was concurrently elevated, indicating functional cross-linking capacity alongside increased synthesis. The authors noted that the copper chelation state was essential – free copper at equivalent concentrations was cytotoxic rather than stimulatory.
Tripeptide-copper complexes accelerate anagen re-entry and perifollicular vascularization in murine telogen skin
Topical application of AHK-Cu to C57BL/6 mice in synchronized telogen phase resulted in significantly earlier anagen re-entry (day 14 vs. day 21 in controls) and a 40% increase in perifollicular capillary density as measured by CD31 immunostaining. VEGF-A mRNA was elevated 1.8-fold in treated dermal tissue. The authors proposed that copper-mediated VEGF induction, rather than direct follicular signaling, was the primary driver of the observed effect.
Clinical assessment of AHK-Cu in a topical formulation for skin barrier function and collagen density: an eight-week randomized controlled study
Forty-two subjects with mild-to-moderate photoaged skin were randomized to AHK-Cu formulation or vehicle twice daily for eight weeks. The treatment group demonstrated a statistically significant reduction in TEWL (mean 18% improvement) and ultrasound-measured dermal density increase of 12% compared to baseline. The vehicle group showed no significant change. Limitations included industry sponsorship, small sample size, and absence of histological confirmation.
From lyophilized powder to a usable solution.
Peptide
5 mg or 10 mg lyophilized powder (supplier-dependent)
Diluent
Sterile water for injection (pH 6.5–7.0 preferred); bacteriostatic water acceptable for multi-use vials. Avoid ascorbic acid-containing diluents - reducing agents may disrupt Cu²⁺ coordination.
Final concentration
Common working concentrations: 0.1–1.0 mg/mL for topical incorporation; 0.01–0.1 mg/mL for subcutaneous research use. Concentration selection should reflect the intended application and available literature precedent.
01
Prepare the vial
02
Draw the diluent
03
Add slowly
04
Prepare the vial
Note
Dosing rythm
A patient titration
The framework below is derived from preclinical literature, cosmeceutical research precedent, and the pharmacological behavior of copper-chelated peptides. No standardized clinical protocol exists; this is an educational reference only.
Storage, caution, contradiction
Storage
Cold, dark, undisturbed
- Store lyophilized powder at −20°C, protected from light and moisture. Stability at this temperature is generally reported as 24 months from manufacture.
- Reconstituted solution should be refrigerated at 2–8°C and used within 14 days. Do not freeze reconstituted peptide - repeated freeze-thaw cycles may disrupt copper coordination.
- Avoid contact with metal instruments during reconstitution. Stainless steel may introduce competing metal ions; use plastic or glass syringes and mixing vessels.
- Protect reconstituted solution from direct light. The copper complex is photosensitive; amber vials or foil wrapping are appropriate for storage beyond 48 hours.
- Do not combine AHK-Cu in solution with strong reducing agents (ascorbic acid, glutathione) or chelating agents (EDTA). These will strip or compete for the Cu²⁺ ion, rendering the complex inactive or unpredictable.
Side effects
What members describe
- Topical application may produce transient erythema or mild pruritus at the application site, particularly at concentrations above 0.5 mg/mL. This typically resolves within 30–60 minutes.
- Subcutaneous injection may cause local discoloration - a faint blue-green tinge attributable to the copper complex - that resolves within 24–48 hours in most preclinical observations.
- Systemic copper accumulation is a theoretical concern with prolonged high-dose use, though the chelated form limits free copper bioavailability. Individuals with Wilson's disease or copper metabolism disorders face elevated risk.
- Mild injection-site reactions (erythema, induration) have been noted in subcutaneous research use. These are consistent with the general profile of peptide injections and are not specific to the copper complex.
- No systemic adverse events have been documented in the published cosmeceutical literature at topical doses. The subcutaneous safety profile in humans is not formally characterized; preclinical data are reassuring but not conclusive.
Contradictions
Reasons to abstain
- Wilson's disease or any confirmed disorder of copper metabolism. The copper ion, even chelated, represents an additional copper load that may be clinically significant in these individuals.
- Known hypersensitivity to copper compounds or any component of the formulation. Contact dermatitis to copper jewelry may indicate relevant sensitization.
- Pregnancy and lactation. No safety data exist in these populations. The copper-chelated structure introduces a theoretical concern regarding fetal copper homeostasis that has not been studied.
- Active skin infection or open wounds at the intended application site for topical use. The angiogenic and remodeling signals of AHK-Cu are not appropriate in the context of uncontrolled infection.
- Concurrent use of systemic copper-chelating medications (e.g., penicillamine, trientine). Pharmacological copper depletion and AHK-Cu supplementation represent opposing interventions; their interaction is unstudied.
Synergies
Good matches for AHK-Cu
AHK-Cu occupies the tissue-remodeling pillar of a regenerative protocol. Its companions are selected for mechanistic complementarity – peptides that address adjacent phases of repair, follicular biology, or extracellular matrix architecture without redundancy. Aeterna does not prescribe combinations; these pairings reflect patterns in the preclinical literature.
FAQ
Your questions, patiently answered
Both are copper-chelated tripeptides derived from human serum albumin, and both carry Cu²⁺ in a histidine-coordinated complex. The difference lies in the flanking amino acids: GHK-Cu carries glycine and lysine; AHK-Cu carries alanine and lysine. This structural variation alters receptor affinity, tissue distribution, and the precise downstream signaling profile. GHK-Cu has a substantially larger published evidence base. AHK-Cu is considered by some researchers to have a more targeted dermal fibroblast activity, though direct comparative human data are limited.
The chelated form of copper in AHK-Cu is fundamentally different from free ionic copper. The tripeptide scaffold coordinates Cu²⁺ in a stable complex that facilitates cellular uptake through established copper transport mechanisms rather than free diffusion. At concentrations used in cosmeceutical research, no systemic copper accumulation has been documented. Individuals with copper metabolism disorders should exercise particular caution and consult a physician before any use.
Both routes appear in the preclinical literature. Topical application is the more extensively studied and more commonly employed route, particularly in cosmeceutical and wound-healing contexts. Subcutaneous use has been explored in animal models. The subcutaneous safety and pharmacokinetic profile in humans has not been formally characterized in peer-reviewed clinical trials. Any subcutaneous use falls strictly within research contexts.
Published cosmeceutical studies have employed protocols of four to twelve weeks, with the eight-week duration appearing most frequently in controlled assessments of collagen density and barrier function. Preclinical wound-healing studies typically observe outcomes over seven to fourteen days. There is no established long-term safety or efficacy data beyond twelve weeks in any published human study.
This is a practically important question. Ascorbic acid (vitamin C) is a reducing agent that can disrupt the Cu²⁺ coordination complex in AHK-Cu, potentially rendering the peptide inactive or releasing free copper ion. Cosmeceutical formulators generally recommend separating AHK-Cu application from high-concentration ascorbic acid products by at least 30 minutes, or avoiding co-formulation entirely. The clinical significance of this interaction at typical topical concentrations has not been rigorously quantified.
No. As of 2025, AHK-Cu carries no regulatory approval from the FDA, EMA, or equivalent authority for any therapeutic indication. It is studied in research and cosmeceutical contexts. Aeterna does not prescribe, dispense, or sell AHK-Cu or any peptide. This monograph is an educational document.
In the same family
Further reading in the curriculum.
Sourcing · Independently verified
When you're ready, source thoughtfully.